SLEEVE GASTRECTOMY TO CORRECT OBESITY AND ASSOCIATED CO-MORBIDITIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Obesity has become a serious health problem and it is a major risk factor for the development of insulin resistance and type 2 diabetes mellitus (T2DM). Laparoscopic sleeve gastrectomy (LSG) has revealed to be effective for achieving weight loss and a potential competitor with other operations. The aim of this study is to evaluate weight loss and the reversibility of associated comorbidities in obese T2DM patients, one and three months after LSG. Data collected between January 1st – June 30th 2011 from 23 subjects with obesity and T2DM were analyzed retrospectively. The following parameters recorded before, one and three months after surgery were compared: body mass index (BMI), fasting plasma glucose, lipid profile, arterial blood pressure, hypoglycemic drugs, antihypertensive and hypolipidemic drugs. Mean BMI decreased from 45.17 ± 8.342kg/m² to 39 ± 6.031kg/m² at one month and to 34.91 ± 4.435kg/m² 3 months after surgery. Fasting plasma glucose decreased to 117.87 ± 35.143mg/dl at one month and to 102.22 ± 16.605mg/dl, 3 months after surgery. Following surgery, a full remission of T2DM was achieved in 39% of patients in the first month and in 65% of patients at 3 months. There was also an important improved in lipid profile, blood pressure control and obstructive sleep apnea (OSA). Our study has shown positive early effects of LSG on obese T2DM patients regarding weight loss and obesity - related comorbidities reduction.